1.83
price up icon2.23%   0.04
after-market アフターアワーズ: 1.88 0.05 +2.73%
loading
前日終値:
$1.79
開ける:
$1.77
24時間の取引高:
5.72M
Relative Volume:
2.86
時価総額:
$399.27M
収益:
$194.75M
当期純損益:
$-51.26M
株価収益率:
-3.5192
EPS:
-0.52
ネットキャッシュフロー:
$-23.38M
1週間 パフォーマンス:
-1.08%
1か月 パフォーマンス:
+2.23%
6か月 パフォーマンス:
+94.68%
1年 パフォーマンス:
+52.50%
1日の値動き範囲:
Value
$1.75
$1.87
1週間の範囲:
Value
$1.74
$1.90
52週間の値動き範囲:
Value
$0.80
$2.48

Akebia Therapeutics Inc Stock (AKBA) Company Profile

Name
名前
Akebia Therapeutics Inc
Name
セクター
Healthcare (1176)
Name
電話
617-871-2098
Name
住所
245 FIRST STREET, CAMBRIDGE, MA
Name
職員
167
Name
Twitter
@akebiatx
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
AKBA's Discussions on Twitter

AKBA を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Specialty & Generic icon
AKBA
Akebia Therapeutics Inc
1.83 399.27M 194.75M -51.26M -23.38M -0.28
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
164.84 74.37B 9.15B 2.43B 2.31B 5.32
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.69 43.81B 14.26B 1.55B 0 0.3383
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
13.10 41.53B 30.27B 1.93B 3.45B 0.6044
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
22.09 25.03B 16.77B -959.00M 1.37B -0.85
Drug Manufacturers - Specialty & Generic icon
VTRS
Viatris Inc
12.52 14.94B 15.05B -883.30M 1.89B -0.74

Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2023-11-29 再開されました BTIG Research Buy
2023-08-28 アップグレード H.C. Wainwright Neutral → Buy
2023-05-31 アップグレード Piper Sandler Neutral → Overweight
2022-03-31 ダウングレード H.C. Wainwright Buy → Neutral
2022-03-31 ダウングレード Mizuho Buy → Neutral
2022-03-31 ダウングレード Needham Buy → Hold
2022-03-31 ダウングレード Piper Sandler Overweight → Neutral
2021-03-08 開始されました Cantor Fitzgerald Overweight
2021-01-29 ダウングレード JP Morgan Neutral → Underweight
2019-11-14 繰り返されました Needham Buy
2019-08-06 繰り返されました H.C. Wainwright Buy
2019-07-11 繰り返されました H.C. Wainwright Buy
2019-05-02 開始されました JP Morgan Overweight
2019-03-20 開始されました Citigroup Neutral
2018-09-07 再開されました Morgan Stanley Equal-Weight
2018-08-10 繰り返されました Needham Buy
2018-06-06 繰り返されました H.C. Wainwright Buy
2017-12-19 開始されました Piper Jaffray Overweight
2017-12-07 開始されました BTIG Research Buy
2017-09-15 開始されました RBC Capital Mkts Sector Perform
2017-07-10 繰り返されました H.C. Wainwright Buy
2017-04-27 繰り返されました H.C. Wainwright Buy
2017-04-27 繰り返されました Needham Buy
2016-12-27 繰り返されました H.C. Wainwright Buy
2016-12-20 繰り返されました JMP Securities Mkt Outperform
2016-11-15 開始されました Aegis Capital Buy
2016-09-29 開始されました Brean Capital Buy
2016-03-16 繰り返されました Needham Buy
2016-01-21 開始されました Credit Suisse Neutral
すべてを表示

Akebia Therapeutics Inc (AKBA) 最新ニュース

pulisher
Dec 21, 2024

404,718 Shares in Akebia Therapeutics, Inc. (NASDAQ:AKBA) Acquired by Wellington Management Group LLP - MarketBeat

Dec 21, 2024
pulisher
Dec 20, 2024

High Growth Tech Stocks To Watch In December 2024 - Simply Wall St

Dec 20, 2024
pulisher
Dec 20, 2024

Investors in Akebia Therapeutics (NASDAQ:AKBA) have unfortunately lost 73% over the last five years - Yahoo Finance

Dec 20, 2024
pulisher
Dec 19, 2024

Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Eastern Progress Online

Dec 19, 2024
pulisher
Dec 19, 2024

CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025 - The Eastern Progress Online

Dec 19, 2024
pulisher
Dec 15, 2024

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus.com

Dec 15, 2024
pulisher
Dec 13, 2024

Akebia Therapeutics (NASDAQ:AKBA) Upgraded by StockNews.com to Hold Rating - MarketBeat

Dec 13, 2024
pulisher
Dec 12, 2024

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Eastern Progress Online

Dec 12, 2024
pulisher
Dec 11, 2024

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference - The Eastern Progress Online

Dec 11, 2024
pulisher
Dec 08, 2024

Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference - Kilgore News Herald

Dec 08, 2024
pulisher
Dec 07, 2024

Akebia Therapeutics to Present at Upcoming Investor Conferences - The Eastern Progress Online

Dec 07, 2024
pulisher
Dec 05, 2024

New Strong Sell Stocks for December 5th - Yahoo Finance

Dec 05, 2024
pulisher
Dec 04, 2024

Akebia Therapeutics (FRA:AX9) EBITDA : €4.0 Mil (TTM As of Sep. 2024) - GuruFocus.com

Dec 04, 2024
pulisher
Dec 03, 2024

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis - Longview News-Journal

Dec 03, 2024
pulisher
Dec 03, 2024

Akebia Therapeutics Awards 121,000 Stock Options to New Employees in Retention Push - StockTitan

Dec 03, 2024
pulisher
Nov 29, 2024

Biotech Alert: Searches spiking for these stocks today - TipRanks

Nov 29, 2024
pulisher
Nov 27, 2024

New Strong Sell Stocks for November 27th - Yahoo Finance

Nov 27, 2024
pulisher
Nov 23, 2024

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GuruFocus.com

Nov 23, 2024
pulisher
Nov 23, 2024

Vadadustat Alternative Dosing Study Results Published in the Ame - GuruFocus.com

Nov 23, 2024
pulisher
Nov 23, 2024

AKBA (Akebia Therapeutics) Future 3-5Y Total Revenue Growth Rate : 9.95 (As of Nov. 23, 2024) - GuruFocus.com

Nov 23, 2024
pulisher
Nov 22, 2024

Akebia Therapeutics to Report Third Quarter 2024 Financial Resul - GuruFocus.com

Nov 22, 2024
pulisher
Nov 22, 2024

Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply C - GuruFocus.com

Nov 22, 2024
pulisher
Nov 22, 2024

Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024 - GuruFocus.com

Nov 22, 2024
pulisher
Nov 20, 2024

Q3 2024 Earnings: Hold Akebia Therapeutics (NASDAQ:AKBA) - Seeking Alpha

Nov 20, 2024
pulisher
Nov 14, 2024

Akebia's FDA-Approved Vafseo Shows Promise in Key Dialysis Trial Results | AKBA Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 14, 2024

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease - Longview News-Journal

Nov 14, 2024
pulisher
Nov 13, 2024

Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by StockNews.com - Defense World

Nov 13, 2024
pulisher
Nov 09, 2024

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024
pulisher
Nov 09, 2024

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50 - Yahoo Finance

Nov 09, 2024
pulisher
Nov 08, 2024

Earnings call: Akebia reports Q3 results, gears up for Vafseo launch - Investing.com Australia

Nov 08, 2024
pulisher
Nov 08, 2024

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 41% - Simply Wall St

Nov 08, 2024
pulisher
Nov 08, 2024

Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... By GuruFocus - Investing.com Canada

Nov 08, 2024
pulisher
Nov 08, 2024

Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: - GuruFocus.com

Nov 08, 2024
pulisher
Nov 08, 2024

Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... - Yahoo Finance

Nov 08, 2024
pulisher
Nov 08, 2024

Akebia Therapeutics: Q3 Earnings Snapshot - CT Insider

Nov 08, 2024
pulisher
Nov 08, 2024

Akebia Therapeutics Prepares for Vafseo Launch - TipRanks

Nov 08, 2024

Akebia Therapeutics Inc (AKBA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Akebia Therapeutics Inc (AKBA) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Dahan Michel
SVP, Chief Operating Officer
May 13 '24
Sale
1.26
34,840
43,898
672,092
Dahan Michel
SVP, Chief Operating Officer
Feb 29 '24
Sale
1.58
8,661
13,684
706,932
Hadas Nicole R.
SVP, Chief Legal Officer
Feb 29 '24
Sale
1.58
5,974
9,439
663,259
Butler John P.
CEO and President
Feb 29 '24
Sale
1.58
46,570
73,581
2,044,580
Burke Steven Keith
SVP, Chief Medical Officer
Feb 29 '24
Sale
1.58
7,169
11,327
695,840
Hadas Nicole R.
SVP, Chief Legal Officer
Feb 27 '24
Sale
1.52
7,411
11,265
669,233
Dahan Michel
SVP, Chief Operating Officer
Feb 27 '24
Sale
1.52
10,744
16,331
715,593
Burke Steven Keith
SVP, Chief Medical Officer
Feb 27 '24
Sale
1.52
8,367
12,718
703,009
Butler John P.
CEO and President
Feb 27 '24
Sale
1.52
37,733
57,354
2,091,150
Butler John P.
CEO and President
Feb 01 '24
Sale
1.68
46,489
78,102
2,128,883
$11.63
price down icon 1.61%
$89.28
price down icon 2.89%
$83.45
price down icon 0.82%
drug_manufacturers_specialty_generic RDY
$15.37
price up icon 1.65%
$135.42
price up icon 0.34%
$12.52
price up icon 3.22%
大文字化:     |  ボリューム (24 時間):